Related Experiment Video
Updated: Jun 26, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Contraceptive hormone use and cardiovascular disease
Chrisandra L Shufelt1, C Noel Bairey Merz
1Women's Heart Center, Division of Cardiology, Department of Medicine, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Contraceptive hormones, commonly oral contraceptives (OCs), prevent pregnancy but require careful risk-benefit assessment. Newer OCs show no increased heart attack risk but still pose a risk for blood clots.
Area of Science:
- Reproductive Medicine
- Cardiovascular Science
- Pharmacology
Background:
- Oral contraceptives (OCs) are widely used for pregnancy prevention.
- Concerns about cardiovascular risks of hormone therapy, prompted by the Women's Health Initiative, necessitate a review of contraceptive hormone safety.
- Existing data suggest potential antiatheromatous effects of contraceptive hormones, but their impact on atherosclerosis, thrombosis, vasomotion, and arrhythmogenesis requires further investigation.
Purpose of the Study:
- To review the safety, efficacy, and side effects of contraceptive hormones, focusing on cardiovascular implications.
- To evaluate the impact of various contraceptive hormone formulations and delivery methods on cardiovascular health.
- To highlight the need for individualized patient assessment and further research on newer formulations.
Main Methods:
- Review of basic science, animal, and human data.
- Analysis of cardiovascular risk data associated with current and newer generation oral contraceptive formulations.
- Examination of data gaps concerning non-oral contraceptive routes and newest formulations.
Main Results:
- Newer generation OCs do not appear to increase myocardial infarction risk for current users.
- A persistent increased risk of venous thromboembolism is associated with current OC use.
- Cardiovascular data for the newest contraceptive hormone formulations (including those with blood pressure-lowering progestins and non-oral routes) are lacking.
Conclusions:
- Contraceptive hormones, like all medications, require individualized risk-benefit assessment for initiation and selection.
- Women aged 35 and older using contraceptive hormones need thorough cardiovascular risk factor screening (hypertension, smoking, diabetes, etc.).
- Further long-term cardiovascular follow-up studies are essential, particularly for menopausal women with prior OC use, to clarify effects on atherosclerosis and cardiovascular events.
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Coronary Artery Disease I: Introduction